BIT ... this combination therapy for HCV will not compete with Sovaldi (Gilead) which is 90% effective across all genotypes without the need for Interferon/riboviran combination.
BIT are behind the eight ball with BIT225
- Forums
- ASX - Day Trading
- DayTrading Oct 10 Morning